Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Bronchitis”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 145 records · Page 8Linked to original sources

Chronic cough due to chronic bronchitis: ACCP evidence-based clinical practice guidelines.

BACKGROUND: Chronic bronchitis is a disease of the bronchi that is manifested by cough and sputum expectoration occurring on most days for at least 3 months of the year and for at least 2 consecutive years when other respiratory or cardiac causes for the chronic productive cough are excluded. The disease is caused by an interaction between noxious inhaled agents (eg, cigarette smoke, industrial pollutants, and other environmental pollutants) and host factors (eg, genetic and respiratory infections) that results in chronic inflammation in the walls and lumen of the airways. As the disease advances, progressive airflow limitation occurs, usually in association with pathologic changes of emphysema. This condition is called COPD. When a stable patient experiences a sudden clinical deterioration with increased sputum volume, sputum purulence, and/or worsening of shortness of breath, this is referred to as an acute exacerbation of chronic bronchitis as long as conditions other than acute tracheobronchitis are ruled out. The purpose of this review is to present the evidence for the diagnosis and treatment of cough due to chronic bronchitis, and to make recommendations that will be useful for clinical practice. METHODS: Recommendations for this section of the review were obtained from data using a National Library of Medicine (PubMed) search dating back to 1950, performed in August 2004, of the literature published in the English language. The search was limited to human studies, using the search terms "cough," "chronic bronchitis," and "COPD." RESULTS: The most effective way to reduce or eliminate cough in patients with chronic bronchitis and persistent exposure to respiratory irritants, such as personal tobacco use, passive smoke exposure, and workplace hazards is avoidance. Therapy with a short-acting inhaled beta-agonist, inhaled ipratropium bromide, and oral theophylline, and a combined regimen of inhaled long-acting beta-agonist and an inhaled corticosteroid may improve cough in patients with chronic bronchitis, but there is no proven benefit for the use of prophylactic antibiotics, oral corticosteroids, expectorants, postural drainage, or chest physiotherapy. For the treatment of an acute exacerbation of chronic bronchitis, there is evidence that inhaled bronchodilators, oral antibiotics, and oral corticosteroids (or in severe cases IV corticosteroids) are useful, but their effects on cough have not been systematically evaluated. Therapy with expectorants, postural drainage, chest physiotherapy, and theophylline is not recommended. Central cough suppressants such as codeine and dextromethorphan are recommended for short-term symptomatic relief of coughing. CONCLUSIONS: Chronic bronchitis due to cigarette smoking or other exposures to inhaled noxious agents is one of the most common causes of chronic cough in the general population. The most effective way to eliminate cough is the avoidance of all respiratory irritants. When cough persists despite the removal of these inciting agents, there are effective agents to reduce or eliminate cough.

Bronchitis, Chronic↗

High seroprevalence of Helicobacter pylori in chronic bronchitis among Chinese population.

An increased seroprevalence of Helicobacter pylori (H. pylori), especially high virulent cytotoxin-associated gene-A (CagA) positive strains, has been found in many extragastrointestinal disorders. Moreover, it has been reported that the risk of chronic bronchitis may be increased in H. pylori infected patients. However, until now there are no data regarding the relationship between H. pylori infection and chronic bronchitis among Chinese population. Therefore the aim of the present study was to assess the seroprevalence of H. pylori and in particular of CagA positive virulent strains in patients with chronic bronchitis among Chinese population. We evaluated 46 patients with chronic bronchitis, 48 age- and sex-matched patients with peptic ulcer and 48 healthy control subjects. All enrolled subjects underwent a serologic test for H. pylori IgG and CagA by enzyme linked-immunosorbent assay (ELISA). There was no significant difference in the seropositivity for these parameters between chronic bronchitis and peptic ulcer groups (86.9% vs 89.6% for anti-H. pylori IgG and 67.4% vs 72.9% for anti-H. pylori-CagA IgG). However, these serological parameters were significantly higher in the patients with chronic bronchitis or peptic ulcer than those in control group, who showed 60.4% for anti-H. pylori IgG seropositivity and 20.8% for anti-H. pylori-CagA IgG seropositivity. Among the patients with chronic bronchitis, no significant difference was found in these serological parameters between the current cigarette smokers and never smokers. This is the first report of a high seroprevalence of H. pylori infection in chronic bronchitis among Chinese population.

Antibodies, Bacterial↗

[Analysis of HLA-DRB1 allele in patients with chronic bronchitis].

OBJECTIVE: To study the difference in HLA-DRB1 allele frequencies between patients with simple chronic bronchitis and with coal worker's pneumoconiosis (CWP) complicated with chronic bronchitis. METHODS: HLA-DRB1 allele frequencies were measured in 37 patients with simple chronic bronchitis and 33 with CWP complicated with chronic bronchitis of Han ethnicity in Shanxi Province using polymerase chain reaction with sequence specific primer, in comparison with those in normal population of the same province. RESULTS: Allele frequency of HLA-DRB1 * 120X was 24.32% in those with simple chronic bronchitis, and that of HLA-DRB1 * 040X was 22.73% in those with CWP complicated with chronic bronchitis, significantly increased than that in normal people with both P < 0.01. There was no significant difference in other alleles between the three groups. CONCLUSION: It suggests that in Han ethnicity of Shanxi Province HLA-DRB1 * 120X allele frequency is associated with simple chronic bronchitis and that of HLA-DRB1 * 040X is associated with CWP complicated with chronic bronchitis.

Alleles↗

Prevalence of chronic bronchitis in farmers according to smoking and atopic skin sensitization.

Development of chronic bronchitis has been shown to depend strongly on smoking habits. Atopy is known to predispose individuals to the development of asthma. Few studies, however, have dealt with the role of the atopic status of the individual as a predisposing factor for chronic bronchitis. In our previous survey among farmers, we observed that chronic bronchitis occurred more often among atopic than non-atopic subjects. Atopy was defined on the basis of past or present atopic manifestations. The association between atopy and chronic bronchitis was re-examined in a separate study of 169 individuals. Using the skin-prick technique we tested these farmers for atopy. The antigen panel included 36 common and farm-related allergens. Among non-smokers with negative skin tests the prevalence of chronic bronchitis was 5.6%, whereas among farmers with positive skin tests (area of at least one skin test reaction equal to 6 mm2 or larger) the prevalence of chronic bronchitis was 15.1%. When age, sex and smoking habits were accounted for statistically, individuals with positive skin tests suffered from chronic bronchitis twice as frequently as subjects with negative skin tests. The predisposing effects of smoking and atopy were of the same order of magnitude. The results of the clinical study of atopy correspond closely to those of the survey study. In the farming population, individuals with an atopic constitution are predisposed to development of chronic bronchitis.

Agricultural Workers' Diseases↗

[Morphometric picture of chronic bronchitis in bronchiectases--morphologic and morphometric changes in the proximal and distal bronchi and bronchioles].

Morphological specific features of proximal and distal bronchi and bronchioles were studied in secondary chronic bronchitis as compared to the primary one basing on the morphometric data. Some specificity was noted in separate forms of secondary bronchitis. Secondary chronic bronchitis is characterized by non-uniform pathological changes in bronchial walls. Wall enlargement, infiltration and sclerosis are more pronounced in secondary chronic bronchitis as compared to the primary one. The relative volume of glands and muscles is less in secondary chronic bronchitis than in the primary one; the Reid index does not differ from the standard in spite of the enlargement of the mucosal inner layer. Atrophic bronchitis is characterized by thinning of mucosal inner layer and decrease in the number of glands. Secondary chronic bronchitis is characterized by narrowing of bronchioles, in contrast to the primary chronic bronchitis where the mean diameter of bronchioles is extended.

Bronchi↗

Clinical features and treatment of acute bronchitis.

Although several surveys rank acute bronchitis as one of the ten most frequent diagnoses made by primary care physicians, its clinical features are poorly defined and treatment with antibiotics is controversial. This study was designed to determine the clinical characteristics that providers use to diagnose acute bronchitis and to examine the use of antibiotics in treating this illness. Charts of patients with the diagnosis of acute bronchitis or upper respiratory tract infection (URI) were randomly selected and progress notes from these visits were reviewed. Signs, symptoms, laboratory tests, and antibiotics prescribed were recorded. Patients with a diagnosis of acute bronchitis had more productive cough, purulent sputum, and abnormal lung examinations than patients with a diagnosis of URI (P less than .05 for each characteristic). Laboratory tests, including chest roentgenograms, were not frequently used in making the diagnosis of acute bronchitis. Antibotics were prescribed for 27 of 29 patients (92 percent) with a diagnosis of acute bronchitis but for only 4 of 19 patients (21 percent) with a diagnosis of URI. Erythromycin was prescribed for 60 percent of patients with acute bronchitis. From this study it can be concluded that providers use the term acute bronchitis to designate a specific clinical syndrome that they treat with antibiotics. Further clinical trials are needed to evaluate the efficacy of such antibiotic therapy.

Acute Disease↗

The prognostic significance of obstructive bronchitis in bronchial cancer.

The correlation between chronic bronchitis and bronchial cancer was studied. The significance of common--or supposedly common--etiological factors, the risk of bronchial cancer among patients with obstructive bronchitis, the operability and survival rates of obstructive bronchitic patients with bronchial cancer were studied and compared to the data of patients with bronchial cancer but without obstructive bronchitis. The distribution of smokers was the same among male patients with bronchial cancer or obstructive bronchitis. Among male patients of the same age and smoking habits, suffering from obstructive bronchitis, the relative incidence rate of bronchial cancer was 5 times higher in group of the 50-60-year-old and 11 times higher in the age group above 60 than in the groups of patients with dyscrinia only. Accordingly, unfavourable prognostical significance for bronchial cancer is attributed to obstructive bronchitis. The authors advocates to screen patients with bronchitis, to start their out-patient care in an early stage, to register theirs spirometric data, and to supervise male patients with obstructive bronchitis radiologically.

Adolescent↗

Genetic markers for chronic bronchitis and peak expiratory flow in the Copenhagen Male Study.

The associations between four major blood groups, ABH secretor status, and complement C3, and chronic bronchitis and peak expiratory flow were examined in 3387 men, aged 55-74 years. Presence of chronic bronchitis was assessed using the British Medical Research Council (BMRC) questionnaire. Men with NS- in the MNS system had significantly less chronic bronchitis than others, i.e. 11.4% versus 16.0% (p < 0.0005). In heavy smokers, both men with NS- and NS+ had significantly less chronic bronchitis than others. Also, Rhesus positive men had less chronic bronchitis than Rhesus negative men, 28.0% versus 38.3% (p < 0.05). Absence of the complement C3 allele C3F was associated with a higher prevalence of chronic bronchitis. No association with chronic bronchitis was found for the AB0 system or the ABH secretor system. No convincing associations were found between genetic markers and mean peak flow. In conclusion, this study has suggested new genetic markers for respiratory disease indicating a partly genetic aetiology of chronic respiratory disease. The MNS, and to some extent the Rhesus blood groups, were associated with chronic bronchitis in middle-aged men. However, this study demonstrates once again that no single blood type can act as a risk indicator of chronic respiratory disease.

ABO Blood-Group System↗

Treatment of acute bronchitis in adults with a pelargonium sidoides preparation (EPs 7630): a randomized, double-blind, placebo-controlled trial.

BACKGROUND: Acute bronchitis is a widespread medical problem, and, although predominantly caused by viruses, antibiotics are still prescribed unnecessarily. Therefore, it is of utmost importance to evaluate the use of alternative treatments for acute bronchitis. OBJECTIVE: To evaluate the efficacy and safety of a Pelargonium sidoides preparation (EPs 7630 is a registered trademark of Dr. Willmar Schwabe GmbH & Co. KG, Karlsruhe, Germany) compared with placebo in patients with acute bronchitis. DESIGN: Randomized, double-blind, placebo-controlled trial using a design with planned interim analyses. SETTING: Six outpatient clinics. PATIENTS: One hundred twenty-four adults with acute bronchitis present </=48 hours, Bronchitis Severity Score (BSS) >/=five points, and informed consent. INTERVENTION: EPs 7630 or placebo (30 drops three times daily) for seven days. MEASUREMENTS: The primary outcome criterion was the change of BSS on day seven. RESULTS: The decrease of BSS from baseline to day seven was 7.2 +/- 3.1 points with EPs 7630 (n = 64) and 4.9 +/- 2.7 points with placebo (n = 60). The 95% confidence interval for the difference of effects between the two treatment groups (EPs 7630 minus placebo) was calculated as (1.21, 3.56) showing a significant improvement of EPs 7630 compared with placebo on day seven (P < .0001). For each of the five individual symptoms, rates of complete recovery were considerably higher in the EPs 7630 group. Within the first four days, onset of treatment effect was recognized in 68.8% of patients in the EPs 7630 group compared with 33.3% of patients in the placebo group (P < .0001). Health-related quality of life improved more in patients treated with EPs 7630 compared with placebo-treated patients. Adverse events occurred in 25 of 124 patients (EPs 7630: 15/64 patients, placebo: 10/60 patients). All adverse events were assessed as nonserious. CONCLUSIONS: EPs 7630 was superior in efficacy compared with placebo in the treatment of adults with acute bronchitis. It may therefore offer an effective alternative for acute bronchitis unless antibiotics are clearly indicated.

Acute Disease↗

Sputum and bronchial submucosal IL-13 expression in asthma and eosinophilic bronchitis.

BACKGROUND: Nonasthmatic eosinophilic bronchitis is a condition characterized by the presence of eosinophilic airway inflammation in the absence of airflow obstruction or airway hyperresponsiveness. In asthma, the T H 2-type cytokine IL-13 has been implicated in the development of airway inflammation and hyperresponsiveness. Whether the expression of IL-13 is different between these 2 conditions is unknown. OBJECTIVE: We sought to investigate whether IL-13 expression is increased in asthma compared with eosinophilic bronchitis. METHODS: Sputum samples from subjects with mild asthma (n = 30) and eosinophilic bronchitis (n = 15) and normal controls (n = 16) were dialyzed, and IL-13 concentration was measured by ELISA. In a subgroup of these patients, IL-13 protein expression in bronchial biopsies was assessed by immunohistochemistry. RESULTS: The concentration of sputum IL-13 was higher in patients with mild asthma than in normal controls ( P = .03) and in patients with eosinophilic bronchitis ( P = .03). The median (interquartile range) number of IL-13 + cells/mm 2 submucosa was significantly higher in asthma 4 (8) than eosinophilic bronchitis 1.7 (1.9) and normal controls 0.5 (1.1; P = .004). Eighty-three percent of the cells expressing IL-13 in the submucosa were eosinophils, and 8% were mast cells. The median (interquartile range) proportion of eosinophils that expressed IL-13 was higher in the subjects with asthma, 16 (10)%, than those with eosinophilic bronchitis, 7 (3)% ( P = .02). CONCLUSION: The increased expression of IL-13 in asthma compared with eosinophilic bronchitis supports the concept that IL-13 may play a critical role in the pathophysiology of asthma.

Adult↗

Helicobacter pylori seroprevalence in patients with chronic bronchitis.

AIM: A high rate of seropositivity for antibodies against Helicobacter pylori has been found in many extra-gastrointestinal diseases. In addition, it has been reported that the risk of chronic bronchitis may be increased in subjects infected with H. pylori. This study was designed to determine the H. pylori seroprevalence in patients with and without chronic bronchitis. MATERIALS AND METHODS: This study enrolled 68 patients with chronic bronchitis (40 men and 28 women, aged 50.5+/-16.2 years (mean+/-standard deviation) and 95 control subjects (60 men and 35 women, aged 51.8+/-15.9 years) matched for age and sex. An enzyme-linked immunosorbent assay immunoglobulin (Ig) G test for H. pylori diagnosis was performed on all enrolled subjects (those with chronic bronchitis and controls). RESULTS: Forty-five of 68 patients with chronic bronchitis (66.1%) and 48 of 95 subjects in the control group (57.7%) tested positive for H. pylori (P=0.008). Rates of H. pylori infection are higher in patients with chronic bronchitis than in the control group. CONCLUSION: The main conclusion of this study is that H. pylori infection is associated with an increased prevalence chronic bronchitis. Further studies should be planned to understand the potential pathogenetic mechanisms that might underlie this association.

Adult↗

Characteristics of bronchoalveolar lavage fluid in patients with sulfur mustard gas-induced asthma or chronic bronchitis.

PURPOSE: To examine the pattern of immunoglobulins and cellular constituents in bronchoalveolar lavage fluid obtained from patients with sulfur mustard gas-induced asthma or chronic bronchitis as compared with healthy control subjects. SUBJECTS AND METHODS: We studied two groups of nonsmoking veterans with either bronchial asthma (n = 21) or chronic bronchitis (n = 28) believed to have been caused by sulfur mustard gas exposure and a third group of healthy, nonsmoking, non-sulfur mustard gas exposed controls (n = 17). Bronchoalveolar lavage was performed in all three groups. The cellular constituents, albumin content, and immunoglobulin concentrations were determined. RESULTS: The three groups did not differ in age or in the serum albumin and immunoglobulin concentrations. The volume of bronchoalveolar lavage fluid recovered was approximately 10% less in the patients with asthma and chronic bronchitis (P = 0.008). The proportions of lymphocytes among the bronchoalveolar lavage cells were similar in all three groups, whereas the proportion of eosinophils was greater in lavage fluid from the asthmatic subjects than in either the healthy control subjects or the patients with chronic bronchitis (P = 0.0001). Both the total number of the recovered cells per milliliter of lavage fluid and the proportion of neutrophils were significantly greater in bronchoalveolar lavage from patients with chronic bronchitis than in healthy subjects or in the patients with asthma (all P <0.001). CONCLUSION: The bronchoalveolar lavage cellular constituents of patients with sulfur mustard gas-induced asthma and chronic bronchitis are similar to those that have been observed previously in patients with asthma and chronic bronchitis from other common causes.

Adult↗

Direct medical costs of chronic obstructive pulmonary disease: chronic bronchitis and emphysema.

In this study we aimed to estimate direct medical costs of Chronic Obstructive Pulmonary Disease (COPD) by disease type; chronic bronchitis and emphysema. This study estimates direct costs in 1996 dollars using a prevalence approach and both aggregate and microcosting. A societal perspective is taken using prevalence, and multiple national, state and local data sources are used to estimate health-care utilization and costs. Chronic bronchitis and emphysema together account for $14.5 billion in annual direct costs. Inpatient costs are greater than outpatient and emergency costs ($8.3 vs. $7.8 billion) and hospital and medication costs account for most resources spent. The high prevalence of chronic bronchitis accounts for its larger total costs ($11.7 billion) compared with emphysema ($2.8 billion). Emphysema, which is more severe, has higher costs per prevalent case ($1341 vs. $816). Hospital stays account for the highest costs, $6.0 billion for chronic bronchitis and $1.9 billion for emphysema. The hospitalization rate, length of stay and average cost per prevalent case are higher for emphysema than for chronic bronchitis. Medication costs are the second highest cost category ($4.4 billion for chronic bronchitis, $0.693 billion for emphysema). The high hospitalization and low home care costs (0.2% of total) suggest underuse of home care and room to shift from acute to preventive care. More attention to healthcare management of chronic bronchitis and emphysema is suggested, and improving inhaler and anti-smoking compliance might be important targets.

Ambulatory Care↗

TH2 cytokine expression in bronchoalveolar lavage fluid T lymphocytes and bronchial submucosa is a feature of asthma and eosinophilic bronchitis.

BACKGROUND: Asthma is characterized by variable airflow obstruction and airway hyperresponsiveness in association with airway inflammation under the influence of T(H)2 cytokines. Eosinophilic bronchitis has similar immunopathology to asthma but without disordered airway physiology. Whether eosinophilic bronchitis is associated with increased expression of T(H)2 cytokines is unknown. OBJECTIVE: We sought to assess the expression of T(H)2 cytokines in eosinophilic bronchitis. METHODS: Expression of activation markers and chemokine receptors from blood and bronchoalveolar lavage (BAL) fluid T cells and the T(H)2 cytokine expression from these T cells and bronchial mucosa biopsy specimens were assessed from subjects with eosinophilic bronchitis, subjects with asthma, and healthy control subjects. RESULTS: The proportion of resting (stimulated) CD4 BAL fluid T cells expressing intracellular IL-4 was significantly higher in the subjects with eosinophilic bronchitis 7.2% (11.4%) and subjects with asthma 5.3% (5.5%) than in healthy control subjects 2.8% (3.9%) (P =.03). The number of IL-4(+) (P <.001) and IL-5(+) (P =.003) cells per square millimeter of bronchial submucosa was significantly higher in the disease groups than in the healthy control subjects. Expression of intracellular IFN-gamma was significantly higher in stimulated blood CD8 T cells from subjects with eosinophilic bronchitis (24%) and asthma (17%) than in the healthy control subjects (5%; P =.003). There were no between-group differences in expression of IFN-gamma in the BAL fluid T cells or in the bronchial submucosa and no differences in expression of activation markers or chemokine receptors. CONCLUSION: These findings support the concept of asthma as a disease associated with activation of T(H)2 lymphocytes in the airway and provide evidence that these cytokines play a role in the development of airway inflammation in eosinophilic bronchitis but suggest that the release of T(H)2 cytokines is not sufficient for the elaboration of disordered airway physiology in asthma.

Adult↗

Asthma in adult patients presenting with symptoms of acute bronchitis in general practice.

OBJECTIVES: To investigate the association between asthma and acute bronchitis in adults and to ascertain criteria to help general practitioners (GPs) differentiate between acute bronchitis and asthma. DESIGN: Descriptive study. SETTING: Primary health care centre in The Netherlands. PATIENTS: 192 patients, aged 18-75 years, not known to have asthma or other pulmonary diseases, attending their GP with cough persisting for at least 2 weeks. METHODS: Patients were considered to have asthma or chronic obstructive pulmonary disease on the basis of a questionnaire on respiratory symptoms, spirometry and methacholine challenge testing. They were classified as having acute bronchitis if, according to international guidelines, coughing was more frequent than normal for at least 2 weeks, but no more than 4 weeks. Furthermore, either expectoration of purulent sputum for a maximum of 2 weeks and/or rhonchi as assessed by auscultation had to be present. By means of logistic regression symptoms, signs and peak expiratory flow measurements were sought to predict which patients with acute bronchitis actually had asthma. RESULTS: Of the 80 (41.7%) subjects with symptoms of acute bronchitis, 29 (36.9%) were patients with asthma. Within the acute bronchitis group, female sex and symptoms of current reported wheeze, reported episodes of attacks of dyspnoea over the last year and symptoms elicited by allergens were of help in identifying patients who actually had asthma. CONCLUSIONS: A considerable proportion of the patients presenting with acute bronchitis are actually patients with asthma. The absence or presence of a few symptoms and female sex may help to differentiate between these disorders.

Adult↗

Occurrence of asthma and chronic bronchitis among female hairdressers. A questionnaire study.

We carried out a retrospective cohort study using a self-administered questionnaire to assess the risk of hairdressers to develop asthma and chronic bronchitis. A representative sample of 4433 female hairdressers and an equal number of shop personnel in employment in 1980 was drawn from the Longitudinal Census Data File of Statistics Finland. Physician-diagnosed asthma, chronic bronchitis, and other respiratory diseases in 1980 and 1995 were inquired about in the respiratory part of the questionnaire. The response rate to the questionnaire was 82% for the hairdressers (n = 3484) and 79% for the referents (n = 3357). The prevalence of asthma among the hairdressers was 5.6% in 1980 and 10.1% in 1995, and the prevalence of chronic bronchitis was 3.9% in 1980 and 5.6% in 1995. The relative risk for asthma (odds ratio [OR]: 1.7, 95% confidence interval [CI]: 1.3 to 2.3 in 1980; and OR: 1.7, 95% CI: 1.4 to 2.2 in 1995) and for chronic bronchitis (OR: 2.2, 95% CI: 1.5 to 3.2 in 1980; and OR: 1.9, 95% CI: 1.4 to 2.6 in 1995) among hairdressers was almost twice that in the reference group. The incidence rate of asthma in 1980 through 1995 was 2.2 and of chronic bronchitis was 1.1 cases per 1000 person-years among hairdressers, whereas the rate in the reference group was 1.3 asthma cases and 0.9 chronic bronchitis cases per 1000 person-years. The relative risk for developing asthma during the 15 years observation time was 1.7 (95% CI: 1.1 to 2.5) and for chronic bronchitis was 1.2 (95% CI: 0.7 to 1.9) among hairdressers, compared with referents. Our results indicate that hairdressers are at higher risk for developing asthma.

Adult↗

Comparison of sputum-ECP levels in bronchial asthma and chronic bronchitis.

Eosinophil cationic protein (ECP) is a cationic protein secreted by eosinophils with toxic properties for the respiratory epithelium. Sputum-ECP levels have been shown to correlate inversely with airflow obstruction in asthma. In the present study we investigated whether ECP concentrations are different between asthmatic patients and patients with chronic bronchitis. Sputum-ECP concentrations from seven patients with bronchial asthma and seven patients with chronic bronchitis matched for FEV1 were compared (FEV1 Asthma: 66.1 +/- 29.0% of predicted; FEV1 Chronic Bronchitis: 65.2 +/- 33.3% of predicted; p = n.s.). Furthermore, sputum-ECP levels in 4 asthmatic patients with severe airflow obstruction and in 1 patient with chronic bronchitis were measured before and after initiation of a 7-day oral therapy with methylprednisolone 20 mg BID. Changes in sputum-ECP values were compared with changes in FEV1 in these 5 patients. Sputum-ECP levels and pulmonary function were measured as previously described (Am Rev Respir Dis 1992: 145: 604). Sputum-ECP levels from asthmatics were significantly elevated compared with patients with chronic bronchitis: asthma: 893.4 +/- 346.2 micrograms/l per g sputum; chronic bronchitis: 30.0 +/- 8.5 micrograms/l per g sputum (p = 0.002). The degree of airway obstruction correlated with the sputum-ECP levels in asthmatic (r = 0.76, p = 0.05), but not in the patients with chronic bronchitis (r = 0.24, p = n.s.).(ABSTRACT TRUNCATED AT 250 WORDS)

Adult↗

Prevalence of chronic bronchitis in an industrial population in North India.

A survey for the prevalence of chronic bronchitis in an industrial population in North India is reported. The prevalence of chronic bronchitis is 12.5 percent in 473 subjects between the ages of 17 and 64 years. The prevalence rate of chronic bronchitis is comparable to that observed in areas of low community air pollution in Europe and North America. There is no age-related rise in the frequency of respiratory symptoms. The consumption of tobacco in these subjects is low and is comparable to tobacco consumption of light smokers. The prevalence of chronic bronchitis in smokers is five times the prevalence in non-smokers and is similar to the values reported for light smokers in other surveys. These observations suggest that cigarette smoking is associated with the development of chronic bronchitis, and the differences in the prevalence rate of chronic bronchitis between this survey and other surveys conducted in Europe and North America are mainly due to differences in smoking habits. Air pollution has a minor effect only and ethnic differences do not appear to play any part. Forced expired volume in one second shows a negative correlation with age. It is lower in asymptomatic smokers than in non-smokers and is lower in chronic bronchitis than in controls.

Adolescent↗